Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Moving Forward On Combo HIV Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead expects a deal "shortly" with Bristol-Myers Squibb and Merck to create a fixed-dose combination of Viread, Emtriva and Sustiva

You may also be interested in...



GSK, Boehringer Ingelheim Discussing Co-Packaged Combivir/Viramune

The companies have signed a “letter of intent” and are talking to FDA about NDA submission requirements. The agreement may test how quickly the agency can approve co-packaged HIV therapies, and how easy it is for manufacturers to negotiate deals.

GSK, Boehringer Ingelheim Discussing Co-Packaged Combivir/Viramune

The companies have signed a “letter of intent” and are talking to FDA about NDA submission requirements. The agreement may test how quickly the agency can approve co-packaged HIV therapies, and how easy it is for manufacturers to negotiate deals.

Merck, Bristol, Gilead Are In Discussions For Combo HIV Therapy

Merck, Bristol-Myers Squibb, and Gilead are in discussion to develop a co-packaged version of three different AIDS drugs for use in the developing world

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel